Cempra Inc (CEMP) was Reiterated by Stifel to “Buy” while Lowering the Price Target of the company shares to $ 47 from a previous price target of $51 . Stifel advised their investors in a research report released on Jun 24, 2016.
Many Wall Street Analysts have commented on Cempra Inc. ROTH Capital Resumed Cempra Inc on Jun 7, 2016 to “Buy”, Price Target of the shares are set at $37.
On the company’s financial health, Cempra Inc reported $-0.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 2, 2016. Analyst had a consensus of $-0.64. The company had revenue of $2.70 million for the quarter, compared to analysts expectations of $3.94 million. The company’s revenue was down -80.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.41 EPS.
Cempra Inc closed down -0.14 points or -0.75% at $18.53 with 6,14,675 shares getting traded on Tuesday. Post opening the session at $18.7, the shares hit an intraday low of $17.79 and an intraday high of $19.38 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Mar 2, 2016, David Moore (Chief Commercial Officer) purchased 500 shares at $16.18 per share price. According to the SEC, on Jan 6, 2016, Dov A Md Goldstein (director) sold 842 shares at $30.07 per share price. On Dec 15, 2015, David W. Oldach (Chief Medical Officer) sold 10,000 shares at $30.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product solithromycin is being developed in oral capsules intravenous or IV and suspension formulations initially for the treatment of community acquired bacterial pneumonia or CABP an infection of the respiratory tract. The Company’s second product is Taksta an antibiotic known as fusidic acid that has been used for decades outside the United States including Western Europe but which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.